Document:

Exhibit
4.3

 

THE
SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

 

SUBORDINATED
CONVERTIBLE PROMISSORY NOTE

 

	$3,000,000	Issuance
    Date: November 8, 2017

 

For
value received, MoviePass Inc., a Delaware corporation (the “Company”), promises to pay to Helios and Matheson
Analytics Inc., a Delaware corporation (the “Holder”), the principal sum of Three Million Dollars ($3,000,000),
or such lesser amount as shall then equal the outstanding principal amount hereunder (the “Principal Amount”).
Interest shall accrue on this Note from the Issuance Date of this Note on the unpaid Principal Amount at a rate equal to 5.00%
per annum, compounded annually and computed on the basis of a 365-day year and the actual number of days elapsed. This Note is
being issued to the Holder pursuant to that certain Second Amended and Restated Subordinated Convertible Note Purchase Agreement,
dated August 18, 2017, as amended from time to time, among the Company, the Holder and a Requisite Majority (as defined therein)
(the “Amended Note Purchase Agreement”), that certain Securities Purchase Agreement, dated August 15, 2017,
as amended on October 6, 2017, by and between the Company and the Holder (the “SPA”), subject to that certain
Waiver Agreement, dated November 6, 2017, by and between the Company and the Holder, and that certain Investment Option Agreement,
dated October 11, 2017, by and between the Company and the Holder (the “Option Agreement”). Capitalized
terms not otherwise defined herein have the meaning given them in the Option Agreement or the SPA, as applicable. This
Note is subject to the following terms and conditions.

 

		1)	Maturity.
                                         While this Note is outstanding, the Principal Amount and any accrued but unpaid interest
                                         under this Note shall be due and payable upon demand of the Holder at any time after
                                         the two-year anniversary of the Issuance Date of this Note first stated above (the “Maturity
                                         Date”). Subject to Section 2 below, interest shall accrue on this Note and
                                         shall be due and payable on the Maturity Date. Notwithstanding the foregoing, the entire
                                         unpaid Principal Amount, together with accrued and unpaid interest thereon, shall become
                                         immediately due and payable upon the commencement of any bankruptcy, insolvency or dissolution
                                         proceeding by the Company, the execution by the Company of a general assignment for the
                                         benefit of creditors, the filing by or against the Company of a petition in bankruptcy
                                         or any petition for relief under the federal bankruptcy act or the continuation of such
                                         petition without dismissal for a period of 90 days or more, or the appointment of a receiver
                                         or trustee to take possession of the property or assets of the Company.

 

		2)	Cancellation
                                         of Note Upon Consummation of SPA Transaction. Upon
                                         the Closing:

 

		a)	this
                                         Note shall be immediately cancelled and of no further force or effect, automatically
                                         and without any action being required on the part of the Holder, and the Company will
                                         be forever released from all of its obligations and liabilities under this Note including
                                         (without limitation) the obligation to pay the Principal Amount and accrued interest;

 

    	1	 	 

     

    

 

		b)	cancellation
                                         of this Note as provided above shall constitute full satisfaction of the Holder’s
                                         obligation to pay the purchase price for $3,000,000 of the Option Shares pursuant to
                                         the Option Agreement; and

 

		c)	the
                                         Holder shall deliver any original executed copy of this Note in the Holder’s possession
                                         to the Company for destruction, provided that any failure by the Holder to deliver such
                                         original executed copy of this Note to the Company shall not affect the automatic cancellation
                                         of this Note as provided by Section 2(a) above.

 

		3)	Next
                                         Equity Conversion.

 

		a)	Next
                                         Equity Financing. If the Holder terminates the SPA due to the Company’s
                                         material breach of any representation, warranty or covenant thereof that remains uncured
                                         within the time frame specified in Section 7.18 of the SPA (an “SPA Termination”),
                                         the outstanding Principal Amount and any accrued but unpaid interest under this Note
                                         (the amount being converted, the “Conversion Amount”) may, at the
                                         Holder’s option, be converted, in whole or in part, into equity securities issued
                                         and sold at the initial closing of the Company’s next equity financing following
                                         such SPA Termination (the “Next Equity Securities”) in a single transaction
                                         or a series of related transactions yielding gross proceeds to the Company of at least
                                         $1,000,000 (excluding the principle amount or accrued interest or any other amounts owing
                                         on any notes, including the Notes (as defined in the Amended Note Purchase Agreement),
                                         converted into capital stock and issued therein) other than an Exempt Issuance (the “Next
                                         Equity Financing”). “Exempt Issuance” means the issuance
                                         of (a) shares of the Company’s common stock, options or other equity-based awards
                                         to employees, officers, directors, consultants or vendors of the Company for services
                                         rendered to the Company pursuant to any stock or option plan or agreement that was duly
                                         adopted for such purpose, by a majority of the non-employee members of the Board of Directors
                                         or a majority of the members of a committee of non-employee directors established for
                                         such purpose, (b) securities upon the exercise or exchange of or conversion of any Notes
                                         issued hereunder and/or other securities exercisable or exchangeable for or convertible
                                         into shares of Company’s common stock issued and outstanding on the date of this
                                         Note, provided that such securities have not been amended since the date of this Note
                                         to increase the number of such securities or to decrease the exercise price, exchange
                                         price or conversion price of such securities (other than in connection with stock splits
                                         or combinations) or to extend the term of such securities and (c) securities issued pursuant
                                         to acquisitions or strategic transactions of other assets or businesses approved by a
                                         majority of the disinterested directors of the Company or the shareholders of the Company
                                         prior to such issuance; provided that (x) the primary purpose of such issuance is not
                                         to raise capital, (y) the purchaser or acquirer of such shares of the Company’s
                                         common stock in such issuance solely consists of either (1) the actual owners of such
                                         assets or securities acquired in such merger or acquisition or (2) the shareholders,
                                         partners or members of the foregoing persons, and (z) the number or amount (as the case
                                         may be) of such shares of the Company’s common stock issued to such person by the
                                         Company shall not be disproportionate to such person’s actual ownership of such
                                         assets or securities to be acquired by the Company (as applicable).

 

		b)	Notice
                                         of Conversion. If this Note is eligible to be converted pursuant to Section 3(a),
                                         at least fifteen (15) business days prior to the proposed initial closing of the Next
                                         Equity Financing, the Company shall deliver written notice to the Holder of this Note
                                         at the address last shown on the records of the Company for the Holder or given by the
                                         Holder to the Company for the purpose of notice or, if no such address appears or is
                                         given, at the place where the principal executive office of the Company is located, notifying
                                         the Holder of the Next Equity Financing, specifying the conversion price, the Principal
                                         Amount and accrued interest of this Note eligible to be converted, the proposed closing
                                         date of the proposed Next Equity Financing requesting the Holder notify the Company of
                                         its election to convert this Note if any, in the manner and at the place designated in
                                         the Company’s notice. A Holder’s election to convert all or a portion of
                                         this Note in connection with the Next Equity Financing must be made at least five (5)
                                         business days before the expected initial closing date of the Next Equity Financing.

 

    	 	2	 

     

    

 

		c)	Terms
                                         of Conversion. The number of shares of Next Equity Securities to be issued upon
                                         such conversion shall be equal to the quotient obtained by dividing (i) the Conversion
                                         Amount by (ii) 80.00% of the cash price per share of the Next Equity Securities sold
                                         in the Next Equity Financing (excluding the Participation Shares, as defined in the Amended
                                         Note Purchase Agreement), rounded down to the nearest whole share (the “Note
                                         Conversion Price”). The issuance of such shares upon such conversion shall
                                         be upon the terms and subject to the conditions applicable to the Next Equity Financing
                                         and the Company’s Certificate of Incorporation, Bylaws, and other corporate governing
                                         documents, as determined by the Company and the investors in the Next Equity Financing
                                         in their sole discretion. The Note Conversion Price, however, shall not be greater than
                                         the quotient obtained by dividing (x) $210,000,000 by (y) the total number of shares
                                         of Common Stock outstanding (assuming full conversion and exercise of all convertible
                                         or exercisable securities other than (i) the Notes (as defined in the Amended Note Purchase
                                         Agreement), (ii) other outstanding convertible notes and (iii) outstanding convertible
                                         equity securities). Upon such conversion of this Note, the Holder hereby agrees to execute
                                         and deliver to the Company all transaction documents related to the Next Equity Financing,
                                         including any purchase agreement and other ancillary agreements, with customary representations
                                         and warranties and transfer restrictions (including, without limitation, a lock-up agreement
                                         in connection with an initial public offering).

 

		4)	Change
                                         of Control. In the event of a Change of Control (as defined below) prior to the
                                         conversion of this Note or repayment in full of this Note, immediately prior to such
                                         Change of Control, this Note shall become immediately due and payable. The term “Change
                                         of Control” means (i) a sale of all or substantially all of the Company’s
                                         assets other than to an Excluded Entity (as defined below), (ii) a merger, consolidation
                                         or other capital reorganization or business combination transaction of the Company with
                                         or into another corporation, limited liability company or other entity other than an
                                         Excluded Entity, or (iii) the consummation of a transaction, or series of related transactions,
                                         in which any “person” (as such term is used in Sections 13(d) and
                                         14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”))
                                         becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange
                                         Act), directly or indirectly, of all of the Company’s then outstanding voting securities.
                                         Notwithstanding the foregoing, a transaction shall not constitute a Change of Control
                                         if its purpose is to (A) change the jurisdiction of the Company’s incorporation,
                                         (B) create a holding company that will be owned in substantially the same proportions
                                         by the persons who hold the Company’s securities immediately before such transaction,
                                         or (C) obtain funding for the Company in a financing that is approved by the Company’s
                                         Board of Directors. An “Excluded Entity” means a corporation or other
                                         entity of which the holders of voting capital stock of the Company outstanding immediately
                                         prior to such transaction are the direct or indirect holders of voting securities representing
                                         at least a majority of the votes entitled to be cast by all of such corporation’s
                                         or other entity’s voting securities outstanding immediately after such transaction.

 

		5)	Mechanics
                                         and Effect of Conversion. No fractional shares of the Company’s capital
                                         stock will be issued upon conversion of this Note. In lieu of any fractional share to
                                         which the Holder would otherwise be entitled, the Company will pay to the Holder in cash
                                         the amount of the unconverted Principal Amount and accrued interest under this Note that
                                         would otherwise be converted into such fractional share. Upon conversion of this Note,
                                         the Holder shall surrender this Note, duly endorsed, at the principal offices of the
                                         Company or any transfer agent of the Company. At its expense, the Company will, as soon
                                         as practicable thereafter, issue the number of Next Equity Securities to which such Holder
                                         is entitled upon such conversion, together with any other securities and property to
                                         which the Holder is entitled upon such conversion under the terms of this Note, including
                                         a check payable to the Holder for any cash amounts payable as described herein and shall
                                         deliver to such Holder, at such principal office, a notice of issuance upon request for
                                         the number of shares to which such Holder is entitled upon such conversion. Upon conversion
                                         of this Note, the Company will be forever released from all of its obligations and liabilities
                                         under this Note with regard to that portion of the principal amount and accrued interest
                                         being converted including (without limitation) the obligation to pay such portion of
                                         the principal amount and accrued interest.

 

    	 	3	 

     

    

 

		6)	Payment;
                                         Prepayment. All payments shall be made in lawful money of the United States of
                                         America at such place as the Holder hereof may from time to time designate in writing
                                         to the Company. Payment shall be credited first to collection costs, if any, then the
                                         accrued interest then due and payable and the remainder shall be applied to principal.
                                         The Company may prepay this Note at any time without penalty only upon written consent
                                         of the Holder.

 

		7)	Stockholders,
                                         Officers and Directors Not Liable. In no event shall any stockholder, officer
                                         or director of the Company be liable for any amounts due or payable pursuant to this
                                         Note.

 

		8)	Subordination.

 

		a)	The
                                         indebtedness evidenced by this Note is hereby expressly subordinated, to the extent and
                                         in the manner hereinafter set forth, in right of payment to the prior payment in full
                                         of all of the Company’s Senior Indebtedness. The Holder further agrees to execute
                                         a form of subordination agreement, as requested by any current or future lender to the
                                         Company, to effect the foregoing subordination. “Senior Indebtedness”
                                         shall mean the principal of and unpaid interest and premium, if any, on (i) indebtedness
                                         of the Company or with respect to which the Company is a guarantor, whether outstanding
                                         on the date hereof or hereafter created, to banks, insurance companies or other lending
                                         or thrift institutions regularly engaged in the business of lending money, whether or
                                         not secured, (ii) any deferrals, renewals or extensions or any debentures, notes or other
                                         evidence of indebtedness issued in exchange for such Senior Indebtedness, (iii) those
                                         certain secured convertible promissory notes issued by the Company pursuant to the Secured
                                         Convertible Promissory Note and Warrant Purchase Agreement dated on May 27, 2016.

 

		b)	Upon
                                         any receivership, assignment for the benefit of creditors, bankruptcy, reorganization,
                                         or arrangement which creditors (whether or not pursuant to bankruptcy or other insolvency
                                         laws), sale of all or substantially all of the assets, dissolution, liquidation, or any
                                         other marshaling of the assets and liabilities of the Company or in the event this Note
                                         shall be declared due and payable, (i) no amount shall be paid by the Company, whether
                                         in cash or property in respect of the principal of or interest on this Note at the time
                                         outstanding, unless and until the full amount of any Senior Indebtedness then outstanding
                                         shall be paid in full, and (ii) no claim or proof of claim shall be filed with the Company
                                         by or on behalf of the holder of this Note which shall assert any right to receive any
                                         payments in respect of the principal of and interest on this Note except subject to the
                                         payment in full all of the Senior Indebtedness then outstanding.

 

		c)	If
                                         an event of default has occurred with respect to any Senior Indebtedness, permitting
                                         the holder thereof to accelerate the maturity thereof, then unless and until such event
                                         of default shall have been cured or waived or shall have ceased to exist, or all Senior
                                         Indebtedness shall have been paid in full, no payment shall be made in respect of the
                                         principal of or interest on this Note.

 

    	 	4	 

     

    

 

		d)	Nothing
                                         contained in the preceding paragraphs shall impair, as between the Company and the Holder,
                                         the obligation of the Company, which is absolute and unconditional, to pay to the Holder
                                         hereof the principal hereof and interest hereon as and when the same shall become due
                                         and payable, or shall prevent the Holder, upon default hereunder, from exercising all
                                         rights, powers and remedies otherwise provided herein or by applicable law, all subject
                                         to the rights, if any, of the holders of Senior Indebtedness under the preceding paragraphs
                                         to receive cash or other properties otherwise payable or deliverable to the Holder pursuant
                                         to this Note.

 

		9)	Interest
                                         Rate Limitation. Notwithstanding anything to the contrary contained in this Note,
                                         the Amended Note Purchase Agreement, the SPA or the Option Agreement, as applicable (the
                                         “Loan Documents”), the interest paid or agreed to be paid under the
                                         Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by
                                         applicable law (the “Maximum Rate”). If the Holder shall receive interest
                                         in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the
                                         principal remaining owed under this Note or, if it exceeds such unpaid principal, refunded
                                         to the Company. In determining whether the interest contracted for, charged, or received
                                         by the Holder exceeds the Maximum Rate, the Holder may, to the extent permitted by applicable
                                         law, (a) characterize any payment that is not principal as an expense, fee, or premium
                                         rather than interest, (b) exclude voluntary prepayments and the effects thereof, and
                                         (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount
                                         of interest throughout the contemplated term of this Note.

 

		10)	Action
                                         to Collect on Note. If action is instituted to collect on this Note, the Company
                                         promises to pay all of each Holder’s costs and expenses, including reasonable attorney’s
                                         fees, incurred in connection with such action.

 

		11)	Loss
                                         of Note. Upon receipt by the Company of evidence satisfactory to it of the loss,
                                         theft, destruction or mutilation of this Note or any Note exchanged for it, and indemnity
                                         satisfactory to the Company (in case of loss, theft or destruction) or surrender and
                                         cancellation of such Note (in the case of mutilation), the Company will make and deliver
                                         in lieu of such Note a new Note of like tenor.

 

		12)	Miscellaneous.

 

		a)	Governing
                                         Law; Venue. The validity, interpretation, construction and performance of this
                                         Note, and all acts and transactions pursuant hereto and the rights and obligations of
                                         the Company and Holder shall be governed, construed and interpreted in accordance with
                                         the laws of the State of California, without giving effect to principles of conflicts
                                         of law. Venue for any legal action under this Note shall be in the state or federal courts
                                         located in the City of Los Angeles in the State of California.

 

		b)	Entire
                                         Agreement. This Note, together with the Amended Note Purchase Agreement, the
                                         SPA, the Option Agreement and the documents referred to therein, constitute the entire
                                         agreement and understanding between the Company and the Holder relating to the subject
                                         matter herein and supersede all prior or contemporaneous discussions, understandings
                                         and agreements, whether oral or written between them relating to the subject matter hereof.

 

		c)	Amendments
                                         and Waivers. Any term of this Note may be amended only with the written consent
                                         of the Company and the Holder. Any amendment or waiver effected in accordance with this
                                         Section 12(c) shall be binding upon the Company, the Holder and each transferee of the
                                         Note or any portion thereof.

 

		d)	Successors
                                         and Assigns. The terms and conditions of this Note shall inure to the benefit
                                         of and be binding upon the respective successors and assigns of the Company and the Holder.
                                         Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer
                                         this Note without the prior written consent of the Company except pursuant to the exercise
                                         of rights by the holder(s) of Helios’ senior secured convertible notes holding
                                         a security interest in Helios’ assets. Subject to the preceding sentence, this
                                         Note may be transferred only upon surrender of the original Note for registration of
                                         transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer
                                         in form satisfactory to the Company. Thereupon, a new note for the same principal amount
                                         and interest will be issued to, and registered in the name of, the transferee. Interest
                                         and principal are payable only to the registered holder of this Note.

 

		e)	Notices.
                                         Any notice, demand or request required or permitted to be given under this Note shall
                                         be in writing and shall be deemed sufficient when delivered personally or by overnight
                                         courier or sent by email, or 48 hours after being deposited in the U.S. mail as certified
                                         or registered mail with postage prepaid, addressed to the party to be notified at such
                                         party’s address as set forth on the signature page, as subsequently modified by
                                         written notice, or if no address is specified on the signature page, at the most recent
                                         address set forth in the Company’s books and records.

 

		f)	Counterparts.
                                         This Note may be executed in any number of counterparts, each of which when so executed
                                         and delivered shall be deemed an original, and all of which together shall constitute
                                         one and the same instrument.

 

[Signature
Page Follows]

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Subordinated Convertible Promissory Note as of the date first set forth above.

 

	 	THE COMPANY:
	 	 
	 	MOVIEPASS INC.
	 	 	 
	 	By: 	/s/ J Mitchell Lowe
	 		(Signature)
	 	Name: 	J Mitchell Lowe
	 	Title: 	CEO

	 	 	 
	 	Address: 	175 Varick, NY, NY 10014

 

	AGREED TO AND ACCEPTED:	 
	 	 	 
	THE HOLDER:	 
	 	 	 
	HELIOS AND MATHESON ANALYTICS INC. 	 
	 	 	 
	By: 	/s/ Stuart Benson	 
		(Signature)	 
	Name: 	Stuart Benson	 
	Title: 	CFO	 
	 	 	 

	Address:	350 Fifth Avenue Suite #7520	 
		New York, NY 10118 	 

 

[Signature Page to the Subordinated Convertible
Promissory Note of MoviePass Inc.]Exhibit 4.4

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

HELIOS
AND MATHESON ANALYTICS INC.

 

	Warrant Shares: ______	Date Earned: _________, 201_
	 	Date Issued: _________, 201_

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Palladium Capital Advisors,
LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and
the conditions hereinafter set forth, at any time on or after the date issued, as set forth above (the “Initial Exercise
Date”), and on or prior to the close of business on the fifth (5th) year anniversary of the Initial Exercise Date (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Helios and Matheson Analytics Inc.,
a Delaware corporation (the “Company”), up to _________ shares (as subject to adjustment hereunder, the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).

 

Section
1.            Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the “Purchase Agreement”), dated November 6, 2017, among the Company and the buyers signatory thereto.

 

     

     

    

 

Section
2.            Exercise.

 

(a)            Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other
office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise in the form annexed
hereto and within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall
have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or
cashier’s check drawn on a United States bank or, if available, pursuant to the cashless exercise procedure specified
in Section 2(c) below. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type
of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of
the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any
objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase
of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time
may be less than the amount stated on the face hereof.

 

(b)          
Exercise Price. The exercise price per
share of the Common Stock under this Warrant shall be $12.06 subject to adjustment hereunder (the “Exercise Price”).

 

(c)           
Cashless Exercise. If at any time after
the one year anniversary of the date of the Purchase Agreement, there is no effective Registration Statement registering, or no
current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A)
= the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

 

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).

 

    2 

     

    

 

(d)          
Mechanics of Exercise.

 

i.           
Delivery of Warrant Shares Upon Exercise.
Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s
prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)
if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the shares are eligible for resale by the
Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery to the address specified
by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the delivery to the Company of the Notice
of Exercise (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been
issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of
such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price
(or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant
Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise.

 

ii.           
Delivery of New Warrants Upon Exercise.
If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant
certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder
to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical
with this Warrant.

 

iii.          
Rescission Rights. If the Company fails
to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery
Date, then the Holder will have the right to rescind such exercise.

 

    3 

     

    

 

iv.            Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the
Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an
open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to
deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which
(x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to
deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to
such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed
rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a
total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an
aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of
the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.

 

v.            
No Fractional Shares or Scrip. No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share
which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a
cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round
up to the next whole share.

 

vi.           
Charges, Taxes and Expenses. Issuance of Warrant
Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued
in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in
the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require,
as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.

 

    4 

     

    

 

vii.             
Closing of Books. The Company will not
close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms
hereof.

 

(e)           Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
affiliates (as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers, directors and
holders of at least 10% of Holder’s outstanding equity interests and voting power are “affiliates” without
conceding that any such Persons are “affiliates” for purposes of federal securities laws,
“Affiliates”), and any other Persons acting as a group together with the Holder or any of the
Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For
purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)
exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and
(ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company convertible
into or exercisable for Common Stock subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes
of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act and the rules
and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the
Holder that such calculation is in compliance with Section 13(d) of the 1934 Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the 1934 Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by
the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of
Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no
event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to
the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.

 

    5 

     

    

 

Section
3.            Certain
Adjustments.

 

(a)           
Stock Dividends and Splits. If the Company,
at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on
shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares
of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall
be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which
the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares
issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.

 

(b)          
[Reserved]

 

    6 

     

    

 

(c)            Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any
such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be
entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a
result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder
until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).

 

(d)          
Pro Rata Distributions. During such time
as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the
issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same
extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    7 

     

    

 

(e)            Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by
the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related
transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share
exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other
Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a
holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company
under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to
written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in
exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with
an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the
relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value
of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under
this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the
Company herein.

 

    8 

     

    

 

(f)          
Calculations. All calculations under this
Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section
3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number
of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(g)         
Notice to Holder.

 

i.           
Adjustment to Exercise Price. Whenever
the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice
setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.              Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the
Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the
Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the
Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.
The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    9 

     

    

 

Section
4.            Transfer
of Warrant.

 

(a)           
Transferability. Subject to compliance
with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of
the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with
a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading
Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

(b)          
New Warrants. This Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the issue date first set forth above and shall
be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

(c)           
Warrant Register. The Company shall register
this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the
name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.

 

    10 

     

    

 

(d)          
Transfer Restrictions. If, at the time
of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either
(i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities
or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements
pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this
Warrant, as the case may be, comply with the provisions of Sections 4.1 and 5.7 of the Purchase Agreement.

 

(e)           
Representation by the Holder. The Holder,
by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire
the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such
Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.

 

Section
5.            Miscellaneous.

 

(a)           
Call Option. If at any time after the
date hereof, (i) the volume weighted average price of the Common Stock for twenty (20) consecutive Trading Days (the “Measurement
Period”) is at least equal to one hundred fifty percent 150% of the Exercise Price (subject to adjustment for forward
and reverse stock splits, recapitalizations, stock dividends and the like after the date hereof), (ii) the average daily volume
of the Common Stock for such Measurement Period is at least 10,000 shares of Common Stock per Trading Day (subject to adjustment
for forward and reverse stock splits, recapitalizations, stock dividends and the like after the date hereof), (iii) the Holder
is not in possession of any information that constitutes, or might constitute, material non public information which was
provided by the Company, and (iv) there is an effective Registration Statement pursuant to which the Holder is permitted to utilize
the prospectus thereunder to resell all of the Warrant Shares, then the Company may, within one (1) Trading Day of the end of
such Measurement Period, call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet
been delivered. To exercise this right, the Company must deliver to the Holder a written notice (the “Call Notice”),
indicating therein the unexercised portion of this Warrant to which such notice applies. Any unexercised portion of this Warrant
for which a Notice of Exercise shall not have been received, will be cancelled at 6:30 p.m. (New York City time) on the thirtieth
(30th) calendar day after the date of the Call Notice.

 

(b)          
No Rights as Stockholder Until Exercise.
This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior
to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.

 

(c)            Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it
(which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such
Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

    11 

     

    

 

(d)          
Saturdays, Sundays, Holidays, etc. If
the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be
a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

 

(e)           
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may
be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

    12 

     

    

 

(f)           
Jurisdiction. All questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions
of the Purchase Agreement.

 

(g)          
Restrictions. The Holder acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless
exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

(h)          
Nonwaiver and Expenses. No course of dealing
or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise
prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

(i)            
Notices. Any notice, request or other
document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the
notice provisions of the Purchase Agreement.

 

(j)            
Limitation of Liability. No provision
hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any
Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

(k)          
Remedies. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its
rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action
for specific performance that a remedy at law would be adequate.

 

(l)           
Successors and Assigns. Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon
the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.

 

    13 

     

    

 

(m)          
Amendment. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

(n)          
Severability. Wherever possible, each
provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

(o)          
Headings. The headings used in this Warrant
are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    14 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.

 

	 	HELIOS
    AND MATHESON ANALYTICS INC.
	 	 	 
	 	By:	 
	 	Name: 	Stuart
    Benson
	 	Title:	Chief
    Financial Officer

 

     

     

    

 

NOTICE
OF EXERCISE

 

TO:
HELIOS AND MATHESON ANALYTICS INC.

 

(1)         The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2)         Payment
shall take the form of (check applicable box):

 

[     
] in lawful money of the United States; or [       ] [if permitted the cancellation of such number of Warrant Shares as is necessary,
in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant
Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(3)         Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)         Accredited
Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities
Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: ______________________________

 

Name
of Authorized Signatory: _________________________________________________

 

Title
of Authorized Signatory: __________________________________________________

 

Date:
______________________________________________________________________

 

     

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 	 
		 	(Please
    Print)
	 	 	 
	Address:	 	 
		 	(Please
    Print)

 

Dated:
_______________, ___, _______________

 

Holder’s
Signature: _______________________

 

Holder’s
Address: ________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]